Health PEI joins global stroke trial to deliver faster, smarter care for Islanders

Health PEI is contributing to a global stroke research study aimed at improving emergency treatment for Islanders experiencing acute stroke. It will explore the most effective dosage of a commonly used clot-busting drug. 

“Islanders are part of a global effort to transform stroke care. By participating in this study, they’re helping us deliver faster, smarter treatment locally, while contributing to research that could improve outcomes for patients worldwide.”

-Dr. Heather Williams, neurologist and chair of Health PEI’s Stroke Steering Committee. 

Immediate treatment is critical in stroke care. Islanders can be automatically enrolled to ensure no time is lost during an emergency. Once stable, they are invited to provide their medical information to researchers. This approach ensures patients receive potentially life-saving treatment without delay, while still preserving their right to consent.

“This study is about giving Islanders the best possible chance at recovery,” said Dr. Williams. “We’re proud to be part of research that prioritizes patient care and advances how we respond to stroke emergencies.”

Funded by the Canadian Institutes of Health Research and led by researchers in Calgary, the trial is expected to begin this fall and will run for 12 to 18 months. Building on 15 years of program progress, findings from the study will be a vital step forward in improving stroke outcomes for Islanders.

Media Contact: 
Stephanie Kelly
Senior Communications Officer, Health PEI
stephaniekelly@ihis.org 

Frequently Asked Questions:

What is Tenecteplase?

Tenecteplase is a clot busting drug proven to treat strokes safely, quickly, and effectively. 

What exactly is being tested in the study? 
The research team is trying to answer: 

• What is the optimal dosage of Tenecteplase to give to patients with a stroke?
• Can Tenecteplase effectively be given to patients on blood thinners?     
• Does NoNO-42, a new neuro-protectant agent, improve stroke outcomes when given along with Tenecteplase?

How many Islanders receive Tenecteplase as stroke treatment?

Only about 15 per cent of stroke patients on PEI qualify for Tenecteplase treatment.

What is NoNO-42? 

NoNO-42 is a new neuroprotectant agent, which helps to keep the brain alive while medical teams work to restore blood flow during a stroke.